These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 2150328)

  • 1. Human monoclonal antibody effective against septicemia.
    Oncology (Williston Park); 1990 Nov; 4(11):74. PubMed ID: 2150328
    [No Abstract]   [Full Text] [Related]  

  • 2. Multicenter evaluation of a human monoclonal antibody to Enterobacteriaceae common antigen in patients with Gram-negative sepsis.
    Albertson TE; Panacek EA; MacArthur RD; Johnson SB; Benjamin E; Matuschak GM; Zaloga G; Maki D; Silverstein J; Tobias JK; Haenftling K; Black G; Cowens JW;
    Crit Care Med; 2003 Feb; 31(2):419-27. PubMed ID: 12576946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Monoclonal antibodies in the treatment of sepsis caused by Gram-negative microorganisms].
    Otero AJ; Linares M
    Rev Cubana Med Trop; 1998; 50(1):31-5. PubMed ID: 9842265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Afelimomab led to a modest mortality benefit in patients with severe sepsis and elevated interleukin-6 levels.
    Rondon E; Venkataraman R
    Crit Care; 2005 Aug; 9(5):E20. PubMed ID: 16277704
    [No Abstract]   [Full Text] [Related]  

  • 5. [Monoclonal antibodies against endotoxin in septicemia. Marketing or scientific evaluation?].
    Waage A
    Tidsskr Nor Laegeforen; 1994 Mar; 114(8):951-3. PubMed ID: 8191476
    [No Abstract]   [Full Text] [Related]  

  • 6. An overview of clinical studies in healthy subjects and patients with severe sepsis with IC14, a CD14-specific chimeric monoclonal antibody.
    Axtelle T; Pribble J
    J Endotoxin Res; 2003; 9(6):385-9. PubMed ID: 14733726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Afelimomab-another therapeutic option in sepsis therapy?
    Grass G; Neugebauer EA
    Crit Care Med; 2004 Nov; 32(11):2343-4. PubMed ID: 15640652
    [No Abstract]   [Full Text] [Related]  

  • 8. [Anticytokine therapy in sepsis and why it fails].
    Chýlek V; Kula R; Holub M; Szturz P; Sklienka P; Máca J
    Klin Mikrobiol Infekc Lek; 2008 Dec; 14(6):209-12. PubMed ID: 19214954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Non-antibiotic treatment of sepsis].
    Møller K; Kronborg G; Pedersen BK
    Ugeskr Laeger; 2000 May; 162(20):2872-5. PubMed ID: 10860425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced survival in Pseudomonas aeruginosa septicemia associated with high levels of circulating antibody to Escherichia coli endotoxin core.
    Pollack M; Huang AI; Prescott RK; Young LS; Hunter KW; Cruess DF; Tsai CM
    J Clin Invest; 1983 Dec; 72(6):1874-81. PubMed ID: 6358257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Septicemia].
    Tattevin P; Michelet C
    Rev Prat; 2004 Jun; 54(12):1351-8. PubMed ID: 15461056
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy of type-specific and cross-reactive murine monoclonal antibodies directed against endotoxin during experimental sepsis.
    Dunn DL; Bogard WC; Cerra FB
    Surgery; 1985 Aug; 98(2):283-90. PubMed ID: 3895540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of monoclonal antibody therapy in the treatment of infectious disease.
    Chmel H
    Am J Hosp Pharm; 1990 Nov; 47(11 Suppl 3):S11-5. PubMed ID: 2275476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-valent human monoclonal antibody preparation against Pseudomonas aeruginosa derived from transgenic mice containing human immunoglobulin loci is protective against fatal pseudomonas sepsis caused by multiple serotypes.
    Lai Z; Kimmel R; Petersen S; Thomas S; Pier G; Bezabeh B; Luo R; Schreiber JR
    Vaccine; 2005 May; 23(25):3264-71. PubMed ID: 15837231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal antibodies to endotoxin in the management of sepsis.
    Fang KC
    West J Med; 1993 Apr; 158(4):393-9. PubMed ID: 8317126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activated protein C for the treatment of severe sepsis.
    Houston G; Cuthbertson BH
    Clin Microbiol Infect; 2009 Apr; 15(4):319-24. PubMed ID: 19416303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pilot study of anti-lipopolysaccharide human monoclonal antibody MAB-T88 in patients with gram-negative sepsis.
    Daifuku R; Panacek EA; Haenftling K; Swenson WK; Prescott AW; Johnson JL
    Hum Antibodies Hybridomas; 1993 Jan; 4(1):36-9. PubMed ID: 8431557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibody therapy for gram-negative sepsis: principles, applications, and controversies.
    Mehra IV; Gottlieb JE; Nash DB
    Pharmacotherapy; 1993; 13(2):128-34. PubMed ID: 8469619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of a protective human monoclonal for the treatment of gram-negative sepsis.
    Larrick JW; Gray O; Deinhart T; Wang J; Flatgaard J; Chong KT
    Prog Clin Biol Res; 1988; 272():383-93. PubMed ID: 3393571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic potential of rat monoclonal antibodies: isotype specificity of antibody-dependent cell-mediated cytotoxicity with human lymphocytes.
    Hale G; Clark M; Waldmann H
    J Immunol; 1985 May; 134(5):3056-61. PubMed ID: 3980990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.